Home » Health » Ranitidine: Invima asks to remove it from the market due to risk – Health

Ranitidine: Invima asks to remove it from the market due to risk – Health


The National Institute for Food and Drug Surveillance (Invima) issued a health alert in which it ordered the withdrawal from the Colombian market of all batches for all oral presentations of ranitidine, a medicine used to control acidity in the stomach and consequently for the management of dyspepsia, ulcers and other imbalances.

This due to the possible risk of the presence of unacceptable levels of Nitrosamine nitrosodimethylamine (NDMA) in the product.

(Also read: 10 days on average it takes a patient to receive a diagnosis of covid)

“Nitrosamines are classified by the International Agency for Research on Cancer (IARC), as “probably carcinogenic” (category 2) and can also be found in tobacco smoke, some processed foods and certain toiletries, “explains Invima.

This product is of high consumption in the world and that is why Invima recommends to withdraw from the market all the products and for people who already use it, consult the doctor and suspend it immediately.

(Also: These are the symptoms of coronavirus that are known so far)

The sale is suspended on oral products and not for injectable forms.

The main effect of ranitidine is to block H2 (histamine) receptors to prevent acid production, mainly at the gastric level.

(We also suggest you read: ‘Evidence emerging that airborne coronavirus’: WHO)

“If you consume the drug ranitidine in any of its oral presentations, you should consider using other approved over-the-counter products for those indications. The population in treatment with this medicine must go to their doctor to change it for an alternative one ”, indicates Invima.

(In other stories: ‘My daughter wanted to look thin and ended up dead in the hands of a doctor’)

HEALTH UNIT

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.